Skin Elements（SKN）株式概要スキンエレメンツ社は、オーストラリアで植物由来のオーガニックスキンケア処方の研究開発を行っている。 詳細SKN ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析Australian市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去5年間で収益は年間4.4%減少しました。 過去1年間で株主の希薄化は大幅に進んだ 収益が 100 万ドル未満 ( A$341K )+1 さらなるリスクすべてのリスクチェックを見るSKN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW488,589 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeINBLROAG488,589 investors already sharing narrativesYour Fair ValueAU$Current PriceAU$0.00516.6k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-10m1m2016201920222025202620282031Revenue AU$239.2kEarnings AU$25.3kAdvancedSet Fair ValueView all narrativesSkin Elements Limited 競合他社McPherson'sSymbol: ASX:MCPMarket cap: AU$18.8mHolista ColltechSymbol: ASX:HCTMarket cap: AU$25.0mStar Combo PharmaSymbol: ASX:S66Market cap: AU$16.2mAnagenicsSymbol: ASX:AN1Market cap: AU$6.9m価格と性能株価の高値、安値、推移の概要Skin Elements過去の株価現在の株価AU$0.00552週高値AU$0.01852週安値AU$0.002ベータ-0.791ヶ月の変化-28.57%3ヶ月変化25.00%1年変化66.67%3年間の変化-37.49%5年間の変化n/aIPOからの変化-97.50%最新ニュースBoard Change • Jun 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Rod Nicholas is the most experienced director on the board, commencing their role in 2026. Independent Non-Executive Director Josh Gordon was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jun 27Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.9 million.Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.9 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.003 Transaction Features: Subsequent Direct Listingお知らせ • Jun 24Skin Elements Limited Announces Board Resignations, Effective June 22, 2026Skin Elements Limited advised that Brett Fraser, Stuart Usher and Robin Armstrong have resigned as directors with such changes effective 22 June 2026.お知らせ • Jun 23Skin Elements Limited Approves the Election of Board of DirectorsSkin Elements Limited announced the results of the Extraordinary General Meeting held on June 23, 2026. The Company approved the appointment of Mr. Frank Knezovic, Mr. Gorakanage Ishan Malinda Peries, and Mr. Harry Michael Spindler as directors.お知らせ • Jun 02Skin Elements Limited Approves Removal of Dr Peter Francis Malone as A DirectorSkin Elements Limited announced that at its EGM held on June 2, 2026, approved that DR PETER FRANCIS MALONE removed as a director.お知らせ • May 14Skin Elements Limited Receive Further Notice from Kingsbury Wealth Pty LtdOn May 14, 2026, Skin Elements Limited announced that it has received a further request to call a meeting of the shareholders of the Company from Kingsbury Wealth Pty Ltd to consider resolutions to remove directors from the board of the Company that an Extraordinary General Meeting of shareholders of the will be held on June 23, 2026. The Company stated that the Company’s other Directors, Peter Francis Malone and Messrs Filippo (Phil) Leone Giglia, Roderick Anthony Nicholas and Joshua Gordon, are not the subject of removal Resolutions at the Meeting. Additionally, the board recommends that shareholders vote against each of the resolutions.最新情報をもっと見るRecent updatesBoard Change • Jun 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Rod Nicholas is the most experienced director on the board, commencing their role in 2026. Independent Non-Executive Director Josh Gordon was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jun 27Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.9 million.Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.9 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.003 Transaction Features: Subsequent Direct Listingお知らせ • Jun 24Skin Elements Limited Announces Board Resignations, Effective June 22, 2026Skin Elements Limited advised that Brett Fraser, Stuart Usher and Robin Armstrong have resigned as directors with such changes effective 22 June 2026.お知らせ • Jun 23Skin Elements Limited Approves the Election of Board of DirectorsSkin Elements Limited announced the results of the Extraordinary General Meeting held on June 23, 2026. The Company approved the appointment of Mr. Frank Knezovic, Mr. Gorakanage Ishan Malinda Peries, and Mr. Harry Michael Spindler as directors.お知らせ • Jun 02Skin Elements Limited Approves Removal of Dr Peter Francis Malone as A DirectorSkin Elements Limited announced that at its EGM held on June 2, 2026, approved that DR PETER FRANCIS MALONE removed as a director.お知らせ • May 14Skin Elements Limited Receive Further Notice from Kingsbury Wealth Pty LtdOn May 14, 2026, Skin Elements Limited announced that it has received a further request to call a meeting of the shareholders of the Company from Kingsbury Wealth Pty Ltd to consider resolutions to remove directors from the board of the Company that an Extraordinary General Meeting of shareholders of the will be held on June 23, 2026. The Company stated that the Company’s other Directors, Peter Francis Malone and Messrs Filippo (Phil) Leone Giglia, Roderick Anthony Nicholas and Joshua Gordon, are not the subject of removal Resolutions at the Meeting. Additionally, the board recommends that shareholders vote against each of the resolutions.New Risk • Mar 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$12.0m (US$8.39m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 4.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (186% increase in shares outstanding). Revenue is less than US$1m (AU$341k revenue, or US$238k). Market cap is less than US$10m (AU$12.0m market cap, or US$8.39m).Board Change • Feb 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Company Secretary & Independent Non-Executive Director Stuart Usher was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 31Skin Elements Limited, Annual General Meeting, Nov 28, 2025Skin Elements Limited, Annual General Meeting, Nov 28, 2025. Location: level 1, westcentre , 1260 hay street, west perth, wa 6005 Australiaお知らせ • Oct 15Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 157,500,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,092,500,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Transaction Features: Subsequent Direct ListingReported Earnings • Oct 04Full year 2025 earnings released: AU$0.002 loss per share (vs AU$0.004 loss in FY 2024)Full year 2025 results: AU$0.002 loss per share (improved from AU$0.004 loss in FY 2024). Revenue: AU$470.0k (up 13% from FY 2024). Net loss: AU$1.73m (loss narrowed 20% from FY 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in FY 2024)Full year 2025 results: AU$0.003 loss per share (improved from AU$0.004 loss in FY 2024). Revenue: AU$470.0k (up 13% from FY 2024). Net loss: AU$1.73m (loss narrowed 20% from FY 2024). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.お知らせ • Mar 13Skin Elements Limited has completed a Follow-on Equity Offering in the amount of AUD 0.643692 million.Skin Elements Limited has completed a Follow-on Equity Offering in the amount of AUD 0.643692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 136,894,740 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 34,335,812 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 43,333,333 Price\Range: AUD 0.003 Transaction Features: Rights OfferingNew Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 78% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-AU$1.6m). Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Revenue is less than US$1m (AU$416k revenue, or US$259k). Market cap is less than US$10m (AU$3.01m market cap, or US$1.87m).お知らせ • Dec 21Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.513692 million.Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.513692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 136,894,740 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 34,335,812 Price\Range: AUD 0.003 Transaction Features: Rights Offeringお知らせ • Oct 30Skin Elements Limited, Annual General Meeting, Nov 29, 2024Skin Elements Limited, Annual General Meeting, Nov 29, 2024. Location: at 1242 hay street, west perth wa 6005 AustraliaReported Earnings • Oct 04Full year 2024 earnings released: AU$0.004 loss per share (vs AU$0.026 loss in FY 2023)Full year 2024 results: AU$0.004 loss per share (improved from AU$0.026 loss in FY 2023). Revenue: AU$416.2k (up 114% from FY 2023). Net loss: AU$2.16m (loss narrowed 81% from FY 2023).Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.003 loss per share (vs AU$0.026 loss in FY 2023)Full year 2024 results: AU$0.003 loss per share (improved from AU$0.026 loss in FY 2023). Revenue: AU$416.2k (up 114% from FY 2023). Net loss: AU$1.87m (loss narrowed 84% from FY 2023).New Risk • Mar 02New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AU$287k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$810k free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-AU$287k). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (AU$183k revenue, or US$119k). Market cap is less than US$10m (AU$2.82m market cap, or US$1.84m). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding).Board Change • Oct 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Phil Giglia was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 05Full year 2023 earnings released: AU$0.026 loss per share (vs AU$0.004 loss in FY 2022)Full year 2023 results: AU$0.026 loss per share (further deteriorated from AU$0.004 loss in FY 2022). Revenue: AU$194.1k (down 86% from FY 2022). Net loss: AU$11.4m (loss widened AU$9.84m from FY 2022).Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.009 loss per share (vs AU$0.004 loss in FY 2022)Full year 2023 results: AU$0.009 loss per share (further deteriorated from AU$0.004 loss in FY 2022). Net loss: AU$4.10m (loss widened 160% from FY 2022).New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.8m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 2.0% per year over the past 5 years. Revenue is less than US$1m (AU$1.4m revenue, or US$898k). Market cap is less than US$10m (AU$3.81m market cap, or US$2.47m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (33% increase in shares outstanding).お知らせ • May 26Skin Elements Limited, Annual General Meeting, Jun 27, 2023Skin Elements Limited, Annual General Meeting, Jun 27, 2023, at 10:30 W. Australia Standard Time. Location: 1242 Hay Street, West Perth West Perth Western Australia Australia Agenda: To consider remuneration report; to consider approval of 10% placement facility; to consider re-election of Filippo Giglia as a director; to consider election of Stuart Douglas usher as a director; to consider ratification of prior issue of optionslisting rule 7.1; to consider ratification of prior issue of optionslisting rule 7.1A; to consider proposed issue of shares and options to 708 capital pty ltd for underwriting fee; to consider proposed issue of options to 708 capital pty ltd for lead manager services; and to consider other issues.Reported Earnings • Mar 03First half 2023 earnings released: AU$0.007 loss per share (vs AU$0.003 loss in 1H 2022)First half 2023 results: AU$0.007 loss per share (further deteriorated from AU$0.003 loss in 1H 2022). Revenue: AU$96.1k (down 19% from 1H 2022). Net loss: AU$2.89m (loss widened 142% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Board Change • Jan 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Phil Giglia was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 17Skin Elements Limited Announces Executive ChangesSkin Elements Limited announced that it has appointed Mr. Stuart Usher as a Non- Executive Director to the Board and as Company Secretary. Mr. Usher is a CPA and Chartered Company Secretary with over 25 years of extensive experience in the management and corporate affairs of public listed companies in Australian and Internationally, including as Company Director and Company Secretary for several other listed public companies. He holds an MBA from the University of Western Australia and has extensive experience across many industries focusing on Corporate & Financial Management, Strategy & Planning, Mergers & Acquisitions, and Investor Relations & Corporate Governance. Mr. Usher's experience is particularly applicable to Skin Elements as an emerging growth company, working with the Board and senior management team to support delivery of financial, operational, and strategic goals and market share as the Company transitions from research & development to commercial operations for its natural antimicrobial technology. Mr. Usher is also appointed as Company Secretary replacing Mr. Phil Giglia in this role. SKN also announced of the resignation of Mr. Lee Christensen as Non-Executive Director to focus on other projects.お知らせ • Oct 19Skin Elements Limited Provides Market UpdateSkin Elements Limited provided the following market update on its business plans including the commercialisation of its all-natural plant-based SE FormulaTM anti-microbial technology. The SE Formula Natural Revolution Skin Elements is at the forefront of this revolution with SE FormulaTM, a high performance proprietary all-natural antimicrobial technology. With global economies emerging from lockdown measures, the focus is on sustainability and environmental impact and increased knowledge and greater awareness of the effects of harmful and aggressive toxic chemical ingredients. People globally are now demanding eco-friendly and biodegradable solutions with improved efficacy and anti-bacterial properties. The SE FormulaTM is the result of more than 15 years research and development by the Skin Elements' team in the area of plant-based ingredients and antimicrobials. It is Australian made from a 100% plant-based proprietary formula that is biodegradable, vegan, non-corrosive, non-flammable and cruelty free. The product does not contain any synthetic chemicals including benzoates, benzalkonium chloride, hydrogen peroxides, quaternary ammonium compounds, bleach/chlorine compounds or other chemical ingredients. The SE FormulaTM is used in the Company's proprietary brands including Invisi-Shield SuprCuvr plant-based hospital grade disinfectant range, the Soléo Organics natural sunscreen brand, the PapayaActivs therapeutic skincare range and the Elizabeth Jane Natural Cosmetics. SuprCuvr (Log 7 /Log 3); SuprCuvr is a TGA registered hospital-grade disinfectant made from a 100% plant-based formula. Independent laboratory tests have confirmed that SuprCuvr has achieved very high effectiveness (99.99999% or 7 log reduction) against COVID 19 and other germs. SuprCuvr is also approved by NASAA as a Certified Organic input which confirms the products use around humans and certified organic food. Skin Elements is ready to play an active role in helping global communities to recover, survive and thrive. With Australia now emerging from COVID-19, SuprCuvr has been positioned as a high performance broad spectrum disinfectant that is safe to use with humans, animals and plants. Furthermore, Skin Elements is providing SuprCuvr at (Log 3 or 99.9%) effective against germs making SuprCuvr extremely price competitive compared to existing chemical disinfectant products. Expanding the SE FormulaTM Product Range; Skin Elements is actively seeking to expand the SuprCuvr product range beyond its use as a hospital-grade disinfectant and by offering new products at different price points. Testing results of SuprCuvr have also shown its ability to kill other potentially-dangerous pathogenic bacteria, including E.coli and Staph.aureus that can be present in-hospital settings, and independent laboratory tests were conducted on the anti-fungal capacity of SuprCuvr. Specifically, it was tested for efficacy against black mould (Aspergillus niger) and Candida albicans, highly prevalent sources of fungal infections in humans. Further trials are currently underway in Australia and New Zealand for treatment of livestock and crops. This positive outcome has the potential to open up new product applications in agriculture and horticulture for SuprCuvr, and the Company plans to progress these opportunities to expand the SE FormulaTM product range.Reported Earnings • Oct 02Full year 2022 earnings released: AU$0.004 loss per share (vs AU$0.009 loss in FY 2021)Full year 2022 results: AU$0.004 loss per share (improved from AU$0.009 loss in FY 2021). Revenue: AU$1.41m (up 388% from FY 2021). Net loss: AU$1.58m (loss narrowed 48% from FY 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.Reported Earnings • Sep 01Full year 2022 earnings releasedFull year 2022 results: Revenue: AU$1.41m (up 388% from FY 2021). Net loss: AU$1.62m (loss narrowed 47% from FY 2021).Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Kevin Christensen was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Lee Christensen was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元SKNAU Personal ProductsAU 市場7D0%6.4%-0.8%1Y66.7%-49.7%1.1%株主還元を見る業界別リターン: SKN過去 1 年間で-49.7 % の収益を上げたAustralian Personal Products業界を上回りました。リターン対市場: SKN過去 1 年間で1.1 % の収益を上げたAustralian市場を上回りました。価格変動Is SKN's price volatile compared to industry and market?SKN volatilitySKN Average Weekly Movement28.1%Personal Products Industry Average Movement12.2%Market Average Movement9.7%10% most volatile stocks in AU Market17.2%10% least volatile stocks in AU Market3.9%安定した株価: SKNの株価は、 Australian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: SKNの 週次ボラティリティ は過去 1 年間で41%から28%に減少しましたが、依然としてAustralian株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2000n/aPeter Maloneskinelementslimited.comスキンエレメンツ社は、オーストラリアで植物由来のオーガニックスキンケア処方の研究開発を行っている。病院グレードの植物性消毒剤「SuprCuvr」、ナチュラル・オーガニック日焼け止め「Soléo Organics」、アルコールフリーのナチュラル除菌剤「Invisi Shield」、非ステロイド性治療クリーム「PapayaActivs」、植物バイオ刺激剤「ECO Nurture」、ナチュラル化粧品「Elizabeth Jane」を提供。同社は代理店や小売店を通じて製品を販売している。スキンエレメンツは2000年に設立され、オーストラリアのウェストパースに本社を置いている。もっと見るSkin Elements Limited 基礎のまとめSkin Elements の収益と売上を時価総額と比較するとどうか。SKN 基礎統計学時価総額AU$15.36m収益（TTM）-AU$4.53m売上高(TTM)AU$340.90k45.0xP/Sレシオ-3.4xPER（株価収益率SKN は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SKN 損益計算書（TTM）収益AU$340.90k売上原価AU$60.97k売上総利益AU$279.93kその他の費用AU$4.81m収益-AU$4.53m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0015グロス・マージン82.11%純利益率-1,329.59%有利子負債／自己資本比率0%SKN の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/02 08:40終値2026/07/02 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Skin Elements Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • Jun 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Rod Nicholas is the most experienced director on the board, commencing their role in 2026. Independent Non-Executive Director Josh Gordon was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jun 27Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.9 million.Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.9 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.003 Transaction Features: Subsequent Direct Listing
お知らせ • Jun 24Skin Elements Limited Announces Board Resignations, Effective June 22, 2026Skin Elements Limited advised that Brett Fraser, Stuart Usher and Robin Armstrong have resigned as directors with such changes effective 22 June 2026.
お知らせ • Jun 23Skin Elements Limited Approves the Election of Board of DirectorsSkin Elements Limited announced the results of the Extraordinary General Meeting held on June 23, 2026. The Company approved the appointment of Mr. Frank Knezovic, Mr. Gorakanage Ishan Malinda Peries, and Mr. Harry Michael Spindler as directors.
お知らせ • Jun 02Skin Elements Limited Approves Removal of Dr Peter Francis Malone as A DirectorSkin Elements Limited announced that at its EGM held on June 2, 2026, approved that DR PETER FRANCIS MALONE removed as a director.
お知らせ • May 14Skin Elements Limited Receive Further Notice from Kingsbury Wealth Pty LtdOn May 14, 2026, Skin Elements Limited announced that it has received a further request to call a meeting of the shareholders of the Company from Kingsbury Wealth Pty Ltd to consider resolutions to remove directors from the board of the Company that an Extraordinary General Meeting of shareholders of the will be held on June 23, 2026. The Company stated that the Company’s other Directors, Peter Francis Malone and Messrs Filippo (Phil) Leone Giglia, Roderick Anthony Nicholas and Joshua Gordon, are not the subject of removal Resolutions at the Meeting. Additionally, the board recommends that shareholders vote against each of the resolutions.
Board Change • Jun 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Rod Nicholas is the most experienced director on the board, commencing their role in 2026. Independent Non-Executive Director Josh Gordon was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jun 27Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.9 million.Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.9 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.003 Transaction Features: Subsequent Direct Listing
お知らせ • Jun 24Skin Elements Limited Announces Board Resignations, Effective June 22, 2026Skin Elements Limited advised that Brett Fraser, Stuart Usher and Robin Armstrong have resigned as directors with such changes effective 22 June 2026.
お知らせ • Jun 23Skin Elements Limited Approves the Election of Board of DirectorsSkin Elements Limited announced the results of the Extraordinary General Meeting held on June 23, 2026. The Company approved the appointment of Mr. Frank Knezovic, Mr. Gorakanage Ishan Malinda Peries, and Mr. Harry Michael Spindler as directors.
お知らせ • Jun 02Skin Elements Limited Approves Removal of Dr Peter Francis Malone as A DirectorSkin Elements Limited announced that at its EGM held on June 2, 2026, approved that DR PETER FRANCIS MALONE removed as a director.
お知らせ • May 14Skin Elements Limited Receive Further Notice from Kingsbury Wealth Pty LtdOn May 14, 2026, Skin Elements Limited announced that it has received a further request to call a meeting of the shareholders of the Company from Kingsbury Wealth Pty Ltd to consider resolutions to remove directors from the board of the Company that an Extraordinary General Meeting of shareholders of the will be held on June 23, 2026. The Company stated that the Company’s other Directors, Peter Francis Malone and Messrs Filippo (Phil) Leone Giglia, Roderick Anthony Nicholas and Joshua Gordon, are not the subject of removal Resolutions at the Meeting. Additionally, the board recommends that shareholders vote against each of the resolutions.
New Risk • Mar 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$12.0m (US$8.39m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 4.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (186% increase in shares outstanding). Revenue is less than US$1m (AU$341k revenue, or US$238k). Market cap is less than US$10m (AU$12.0m market cap, or US$8.39m).
Board Change • Feb 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Company Secretary & Independent Non-Executive Director Stuart Usher was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 31Skin Elements Limited, Annual General Meeting, Nov 28, 2025Skin Elements Limited, Annual General Meeting, Nov 28, 2025. Location: level 1, westcentre , 1260 hay street, west perth, wa 6005 Australia
お知らせ • Oct 15Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 157,500,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,092,500,000 Price\Range: AUD 0.002 Discount Per Security: AUD 0.00012 Transaction Features: Subsequent Direct Listing
Reported Earnings • Oct 04Full year 2025 earnings released: AU$0.002 loss per share (vs AU$0.004 loss in FY 2024)Full year 2025 results: AU$0.002 loss per share (improved from AU$0.004 loss in FY 2024). Revenue: AU$470.0k (up 13% from FY 2024). Net loss: AU$1.73m (loss narrowed 20% from FY 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in FY 2024)Full year 2025 results: AU$0.003 loss per share (improved from AU$0.004 loss in FY 2024). Revenue: AU$470.0k (up 13% from FY 2024). Net loss: AU$1.73m (loss narrowed 20% from FY 2024). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
お知らせ • Mar 13Skin Elements Limited has completed a Follow-on Equity Offering in the amount of AUD 0.643692 million.Skin Elements Limited has completed a Follow-on Equity Offering in the amount of AUD 0.643692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 136,894,740 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 34,335,812 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 43,333,333 Price\Range: AUD 0.003 Transaction Features: Rights Offering
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 78% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-AU$1.6m). Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Revenue is less than US$1m (AU$416k revenue, or US$259k). Market cap is less than US$10m (AU$3.01m market cap, or US$1.87m).
お知らせ • Dec 21Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.513692 million.Skin Elements Limited has filed a Follow-on Equity Offering in the amount of AUD 0.513692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 136,894,740 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 34,335,812 Price\Range: AUD 0.003 Transaction Features: Rights Offering
お知らせ • Oct 30Skin Elements Limited, Annual General Meeting, Nov 29, 2024Skin Elements Limited, Annual General Meeting, Nov 29, 2024. Location: at 1242 hay street, west perth wa 6005 Australia
Reported Earnings • Oct 04Full year 2024 earnings released: AU$0.004 loss per share (vs AU$0.026 loss in FY 2023)Full year 2024 results: AU$0.004 loss per share (improved from AU$0.026 loss in FY 2023). Revenue: AU$416.2k (up 114% from FY 2023). Net loss: AU$2.16m (loss narrowed 81% from FY 2023).
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.003 loss per share (vs AU$0.026 loss in FY 2023)Full year 2024 results: AU$0.003 loss per share (improved from AU$0.026 loss in FY 2023). Revenue: AU$416.2k (up 114% from FY 2023). Net loss: AU$1.87m (loss narrowed 84% from FY 2023).
New Risk • Mar 02New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AU$287k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$810k free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-AU$287k). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (AU$183k revenue, or US$119k). Market cap is less than US$10m (AU$2.82m market cap, or US$1.84m). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding).
Board Change • Oct 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Phil Giglia was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 05Full year 2023 earnings released: AU$0.026 loss per share (vs AU$0.004 loss in FY 2022)Full year 2023 results: AU$0.026 loss per share (further deteriorated from AU$0.004 loss in FY 2022). Revenue: AU$194.1k (down 86% from FY 2022). Net loss: AU$11.4m (loss widened AU$9.84m from FY 2022).
Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.009 loss per share (vs AU$0.004 loss in FY 2022)Full year 2023 results: AU$0.009 loss per share (further deteriorated from AU$0.004 loss in FY 2022). Net loss: AU$4.10m (loss widened 160% from FY 2022).
New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.8m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 2.0% per year over the past 5 years. Revenue is less than US$1m (AU$1.4m revenue, or US$898k). Market cap is less than US$10m (AU$3.81m market cap, or US$2.47m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (33% increase in shares outstanding).
お知らせ • May 26Skin Elements Limited, Annual General Meeting, Jun 27, 2023Skin Elements Limited, Annual General Meeting, Jun 27, 2023, at 10:30 W. Australia Standard Time. Location: 1242 Hay Street, West Perth West Perth Western Australia Australia Agenda: To consider remuneration report; to consider approval of 10% placement facility; to consider re-election of Filippo Giglia as a director; to consider election of Stuart Douglas usher as a director; to consider ratification of prior issue of optionslisting rule 7.1; to consider ratification of prior issue of optionslisting rule 7.1A; to consider proposed issue of shares and options to 708 capital pty ltd for underwriting fee; to consider proposed issue of options to 708 capital pty ltd for lead manager services; and to consider other issues.
Reported Earnings • Mar 03First half 2023 earnings released: AU$0.007 loss per share (vs AU$0.003 loss in 1H 2022)First half 2023 results: AU$0.007 loss per share (further deteriorated from AU$0.003 loss in 1H 2022). Revenue: AU$96.1k (down 19% from 1H 2022). Net loss: AU$2.89m (loss widened 142% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Board Change • Jan 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Phil Giglia was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 17Skin Elements Limited Announces Executive ChangesSkin Elements Limited announced that it has appointed Mr. Stuart Usher as a Non- Executive Director to the Board and as Company Secretary. Mr. Usher is a CPA and Chartered Company Secretary with over 25 years of extensive experience in the management and corporate affairs of public listed companies in Australian and Internationally, including as Company Director and Company Secretary for several other listed public companies. He holds an MBA from the University of Western Australia and has extensive experience across many industries focusing on Corporate & Financial Management, Strategy & Planning, Mergers & Acquisitions, and Investor Relations & Corporate Governance. Mr. Usher's experience is particularly applicable to Skin Elements as an emerging growth company, working with the Board and senior management team to support delivery of financial, operational, and strategic goals and market share as the Company transitions from research & development to commercial operations for its natural antimicrobial technology. Mr. Usher is also appointed as Company Secretary replacing Mr. Phil Giglia in this role. SKN also announced of the resignation of Mr. Lee Christensen as Non-Executive Director to focus on other projects.
お知らせ • Oct 19Skin Elements Limited Provides Market UpdateSkin Elements Limited provided the following market update on its business plans including the commercialisation of its all-natural plant-based SE FormulaTM anti-microbial technology. The SE Formula Natural Revolution Skin Elements is at the forefront of this revolution with SE FormulaTM, a high performance proprietary all-natural antimicrobial technology. With global economies emerging from lockdown measures, the focus is on sustainability and environmental impact and increased knowledge and greater awareness of the effects of harmful and aggressive toxic chemical ingredients. People globally are now demanding eco-friendly and biodegradable solutions with improved efficacy and anti-bacterial properties. The SE FormulaTM is the result of more than 15 years research and development by the Skin Elements' team in the area of plant-based ingredients and antimicrobials. It is Australian made from a 100% plant-based proprietary formula that is biodegradable, vegan, non-corrosive, non-flammable and cruelty free. The product does not contain any synthetic chemicals including benzoates, benzalkonium chloride, hydrogen peroxides, quaternary ammonium compounds, bleach/chlorine compounds or other chemical ingredients. The SE FormulaTM is used in the Company's proprietary brands including Invisi-Shield SuprCuvr plant-based hospital grade disinfectant range, the Soléo Organics natural sunscreen brand, the PapayaActivs therapeutic skincare range and the Elizabeth Jane Natural Cosmetics. SuprCuvr (Log 7 /Log 3); SuprCuvr is a TGA registered hospital-grade disinfectant made from a 100% plant-based formula. Independent laboratory tests have confirmed that SuprCuvr has achieved very high effectiveness (99.99999% or 7 log reduction) against COVID 19 and other germs. SuprCuvr is also approved by NASAA as a Certified Organic input which confirms the products use around humans and certified organic food. Skin Elements is ready to play an active role in helping global communities to recover, survive and thrive. With Australia now emerging from COVID-19, SuprCuvr has been positioned as a high performance broad spectrum disinfectant that is safe to use with humans, animals and plants. Furthermore, Skin Elements is providing SuprCuvr at (Log 3 or 99.9%) effective against germs making SuprCuvr extremely price competitive compared to existing chemical disinfectant products. Expanding the SE FormulaTM Product Range; Skin Elements is actively seeking to expand the SuprCuvr product range beyond its use as a hospital-grade disinfectant and by offering new products at different price points. Testing results of SuprCuvr have also shown its ability to kill other potentially-dangerous pathogenic bacteria, including E.coli and Staph.aureus that can be present in-hospital settings, and independent laboratory tests were conducted on the anti-fungal capacity of SuprCuvr. Specifically, it was tested for efficacy against black mould (Aspergillus niger) and Candida albicans, highly prevalent sources of fungal infections in humans. Further trials are currently underway in Australia and New Zealand for treatment of livestock and crops. This positive outcome has the potential to open up new product applications in agriculture and horticulture for SuprCuvr, and the Company plans to progress these opportunities to expand the SE FormulaTM product range.
Reported Earnings • Oct 02Full year 2022 earnings released: AU$0.004 loss per share (vs AU$0.009 loss in FY 2021)Full year 2022 results: AU$0.004 loss per share (improved from AU$0.009 loss in FY 2021). Revenue: AU$1.41m (up 388% from FY 2021). Net loss: AU$1.58m (loss narrowed 48% from FY 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Sep 01Full year 2022 earnings releasedFull year 2022 results: Revenue: AU$1.41m (up 388% from FY 2021). Net loss: AU$1.62m (loss narrowed 47% from FY 2021).
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Kevin Christensen was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Lee Christensen was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
